Why a new Alzheimer's drug is having a slow US debut
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Two big factors behind the slow debut, experts say, are scant insurance coverage and a long setup time needed by many health systems. Patients who surmount those challenges…
#leqembi #eisai #fda #libbyholman #medicare #robertegge #biogensaduhelm #healthinsuranceplans #centersformedicare #medicaidservices
